Advertisement

Topics

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017

Summary

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Galectin3 is a protein encoded by the LGALS3 gene. It mediates with the alpha3, beta1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a premRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 pipeline Target constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 12 and 4 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Musculoskeletal Disorders, Ophthalmology, Undisclosed, Immunology and Metabolic Disorders which include indications Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Atopic Dermatitis, Fibrosis, Liver Cirrhosis, NonAlcoholic Steatohepatitis NASH, Portal Hypertension, Prostate Cancer, Pulmonary Arterial Hypertension, Pulmonary Fibrosis, Unspecified, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Breast Cancer, Colorectal Cancer, Corneal Neovascularization, Diabetic Nephropathy, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca Dry Eye, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma Kahler Disease, NonSmall Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis Psoriasis Vulgaris and Sarcomas.

The latest report Galectin 3 Pipeline Review, H1 2017, outlays comprehensive information on the Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3
The report reviews Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics and enlists all their major and minor projects
The report assesses Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

NEXT ARTICLE

More From BioPortfolio on "Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...